Skip to content

Self-sampling for Non-attenders to Cervical Cancer Screening

Cervical Cancer Prevention Using Self-sampling and Human Papillomavirus Detection

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04226313
Acronym
KOPRETINA
Enrollment
15000
Registered
2020-01-13
Start date
2019-09-23
Completion date
2026-12-01
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection

Keywords

human papillomavirus, HPV, self-sampling, cervicovaginal swab, cervical cancer screening, non-attendance

Brief summary

The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.

Detailed description

Despite the existence of an effective cervical cancer screening in the Czech Republic, cervical cancer is the cause of about 800 new cases and 400 deaths every year. One of the major problem of the Czech cervical cancer screening is low participation. An effective strategy to increase cervical cancer screening attendance is one of the main challenges. The offering of self-sampling to the cervical cancer screening non-attenders could increase women's participation as was shown in several European countries. The trial should determine acceptability of the self-sampling followed by HPV DNA test by Czech women and therefore usability of the self-sampling device to increase cervical cancer screening attendance among under-screened women. Three different approaches will be tested: women will receive a self-sampling device by mail (Arm A); receive a self-sampling device by gynecologist (Arm B); receive a self-sampling device by general practitioner (Arm C). Comparisons of the screening attendance among the arms will be made. To address also potential effects on inequities, the analyses will include comparisons by sociodemographic characteristics. Women from the database of commercial vendor will be included to the Arm A regardless of whether or not they participate in cervical cancer screening program. Women who do not participate in cytology-based cervical cancer screening program for at least three years will be included through their gynecologist (Arm B) or general practitioner (Arm C) database. The second focus of the trial is the evaluation of high-risk human papillomavirus prevalence in screening population of Czech women (attenders and non-attenders of cervical cancer screening) since there are no relevant data for the Czech Republic. Study participants may volunteer for archiving of remaining biological materials for future studies.

Interventions

DIAGNOSTIC_TESTSelf-sampling by Evalyn Brush

Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.

DIAGNOSTIC_TESTSelf sampling by Evalyn Brush home or in GP´s clinic

Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush

Sponsors

The Institute of Molecular and Translational Medicine, Czech Republic
Lead SponsorOTHER
National Institute for Cancer Research, Czech Republic
CollaboratorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Women with age 30-65 years; for arm A women \> 65 years are allowed * Women live in the Czech Republic. * Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C). * Women with completed informed consent. * Women capable of self-sampling of cervicovaginal swab.

Exclusion criteria

* Pregnant women. * Women with no sexual intercourse experience. * Women after hysterectomy including cervix.

Design outcomes

Primary

MeasureTime frameDescription
Screening participation12 monthsComparison of the percentages of women who return a cervicovaginal swab sampled by self-sampling device in different arms of the study. Identification of the best approach to address women who do not participate in standard cervical cancer screening program
Prevalence of high-risk HPV12 monthsEvaluation of the prevalence of high-risk human papillomavirus infection in screening population of Czech women within different arms of the study (attenders/non-attenders).

Secondary

MeasureTime frameDescription
Sociodemographic characteristics12 monthsComparison the distribution of sociodemographic characteristics (education, age, place of residence) and reasons for previous non-attendance for screening by intervention and attendance status in women who return a questionnaire.

Countries

Czechia

Contacts

CONTACTMarian Hajduch, MD, PhD.
marian.hajduch@upol.cz+420 585 632 083
CONTACTVladimira Koudelakova, MSc, Ph.D.
vladimira.koudelakova@upol.cz+420 585 632 089
STUDY_DIRECTORMarian Hajduch, MD, PhD.

IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026